SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $60,113.22 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 7,394 shares of the business’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $8.13, for a total transaction of $60,113.22. Following the sale, the insider owned 200,993 shares of the company’s stock, valued at $1,634,073.09. This trade represents a 3.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Tuesday, August 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.68, for a total value of $43,400.00.
• On Wednesday, August 12th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.52, for a total value of $37,600.00.
• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.66, for a total transaction of $28,300.00.
• On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total transaction of $28,500.00.

SOPHiA GENETICS Stock Performance

Shares of SOPH stock opened at $7.41 on Friday. The firm has a 50-day moving average of $7.91 and a 200-day moving average of $6.16. The company has a market cap of $621.62 million, a P/E ratio of -6.44 and a beta of 0.95. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. SOPHiA GENETICS SA has a one year low of $3.75 and a one year high of $8.98.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. The firm had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. Equities research analysts forecast that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on SOPH shares. HC Wainwright upped their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. BTIG Research boosted their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $10.00.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of hedge funds have recently modified their holdings of SOPH. AWM Investment Company Inc. bought a new position in SOPHiA GENETICS during the second quarter valued at $9,809,000. Hodges Capital Management Inc. purchased a new stake in SOPHiA GENETICS during the first quarter valued at about $2,157,000. Sei Investments Co. purchased a new stake in SOPHiA GENETICS during the first quarter valued at about $1,772,000. Maven Securities LTD bought a new position in SOPHiA GENETICS during the second quarter worth about $866,000. Finally, Hennion & Walsh Asset Management Inc. bought a new position in SOPHiA GENETICS during the second quarter worth about $567,000. Institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.